Single dose of psilocybin improves depressive symptoms in Phase 2 study.

Authors
Category Primary study
JournalBrown University Psychopharmacology Update
Year 2023
A single 25‐mg dose of psilocybin administered with psychological support led to significant and sustained improvement in depressive symptoms compared with placebo in a Phase 2 study of patients with major depressive disorder. A higher number of adverse events occurred in the psilocybin group, but no serious treatment‐emergent adverse events were reported. Study results were published online Aug. 31, 2023, in JAMA.
Epistemonikos ID: f95ca267fb86c8edc0ce6ab9b89afe1214a5c9aa
First added on: Jan 02, 2024